Ruibo Xia

Diagnosis of ankylosing spondylitis

Background: The pathogenesis and pathological progression of ankylosing spondylitis (AS) remain unclear. Owing to the absence of a gold standard for diagnosing AS, diagnostic delays are frequently encountered in clinical practice, exacerbating the disease burden. In the past 16 y...

Safety of TNF-α inhibitors, IL-17 inhibitors, and JAK inhibitors in the treatment of axial spondyloarthritis: a protocol for a multi-method study integrating FAERS data mining, dose–response network meta-analysis, and drug-target Mendelian randomization

Biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs), including tumor necrosis factor-α inhibitors (TNFi), interleukin-17 inhibitors (IL-17i), and Janus kinase inhibitors (JAKi), are standard treatments for axial spondyloarthritis (axSpA). However...